BACKGROUND: Rilpivirine is listed as an alternative key drug in current antiretroviral therapy (ART) guidelines. E138G/A/K in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are rilpivirine resistance-associated mutations and can be identified in a few ART-naive patients, although at low frequency. The 138th position in HIV-1 RT is located in one of the putative epitopes of human leukocyte antigen (HLA)-B*18-restricted cytotoxic T lymphocytes (CTLs). CTL-mediated immune pressure selects escape mutations within the CTL epitope. Here we tested whether E138G/A/K could be selected by HLA-B*18-restricted CTLs. METHODS: The amino acid variation at the 138th position was compared between ART-naive HIV-1-infected patients with and without HLA-B*18. The optimal epitope containing the 138th position was determined and the impact of E138G/A/K on CTL response was analyzed by epitope-specific CTLs. The effect of E138G/A/K on drug susceptibility was determined by constructing recombinant HIV-1 variants. RESULTS: The prevalence of E138G/A/K was 21% and 0.37% in 19 and 1088 patients with and without HLA-B*18, respectively (odds ratio, 72.3; P = 4.9 × 10(-25)). The CTL response was completely abolished by the substitution of E138G/A/K in the epitope peptide. E138G/A/K conferred 5.1-, 7.1-, and 2.7-fold resistance to rilpivirine, respectively. CONCLUSIONS: E138G/A/K can be selected by HLA-B*18-restricted CTLs and confer significant rilpivirine resistance. We recommend drug resistance testing before the introduction of rilpivirine-based ART in HLA-B*18-positive patients.
BACKGROUND:Rilpivirine is listed as an alternative key drug in current antiretroviral therapy (ART) guidelines. E138G/A/K in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are rilpivirine resistance-associated mutations and can be identified in a few ART-naive patients, although at low frequency. The 138th position in HIV-1 RT is located in one of the putative epitopes of human leukocyte antigen (HLA)-B*18-restricted cytotoxic T lymphocytes (CTLs). CTL-mediated immune pressure selects escape mutations within the CTL epitope. Here we tested whether E138G/A/K could be selected by HLA-B*18-restricted CTLs. METHODS: The amino acid variation at the 138th position was compared between ART-naive HIV-1-infectedpatients with and without HLA-B*18. The optimal epitope containing the 138th position was determined and the impact of E138G/A/K on CTL response was analyzed by epitope-specific CTLs. The effect of E138G/A/K on drug susceptibility was determined by constructing recombinant HIV-1 variants. RESULTS: The prevalence of E138G/A/K was 21% and 0.37% in 19 and 1088 patients with and without HLA-B*18, respectively (odds ratio, 72.3; P = 4.9 × 10(-25)). The CTL response was completely abolished by the substitution of E138G/A/K in the epitope peptide. E138G/A/K conferred 5.1-, 7.1-, and 2.7-fold resistance to rilpivirine, respectively. CONCLUSIONS:E138G/A/K can be selected by HLA-B*18-restricted CTLs and confer significant rilpivirine resistance. We recommend drug resistance testing before the introduction of rilpivirine-based ART in HLA-B*18-positive patients.
Authors: Thabo Diphoko; Simani Gaseitsiwe; Ishmael Kasvosve; Sikhulile Moyo; Harriet Okatch; Rosemary Musonda; Mark Wainberg; Joseph Makhema; Richard Marlink; Vladimir Novitsky; Max Essex Journal: AIDS Res Hum Retroviruses Date: 2018-06-12 Impact factor: 2.205
Authors: Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme Journal: Curr Opin HIV AIDS Date: 2019-05 Impact factor: 4.283
Authors: Hiroyuki Gatanaga; Zabrina L Brumme; Emily Adland; Gustavo Reyes-Terán; Santiago Avila-Rios; Carlos R Mejía-Villatoro; Tsunefusa Hayashida; Takayuki Chikata; Giang Van Tran; Kinh Van Nguyen; Rita I Meza; Elsa Y Palou; Humberto Valenzuela-Ponce; Juan M Pascale; Guillermo Porras-Cortés; Marvin Manzanero; Guinevere Q Lee; Jeffrey N Martin; Mary N Carrington; Mina John; Simon Mallal; Art F Y Poon; Philip Goulder; Masafumi Takiguchi; Shinichi Oka Journal: AIDS Date: 2017-09-10 Impact factor: 4.177
Authors: Kristof Theys; Kristel Van Laethem; Perpetua Gomes; Guy Baele; Andrea-Clemencia Pineda-Peña; Anne-Mieke Vandamme; Ricardo J Camacho; Ana B Abecasis Journal: AIDS Res Hum Retroviruses Date: 2016-01-29 Impact factor: 2.205
Authors: Duncan S Palmer; Isaac Turner; Sarah Fidler; John Frater; Dominique Goedhals; Philip Goulder; Kuan-Hsiang Gary Huang; Annette Oxenius; Rodney Phillips; Roger Shapiro; Cloete van Vuuren; Angela R McLean; Gil McVean Journal: Nat Commun Date: 2019-07-09 Impact factor: 14.919
Authors: Huyen Nguyen; Christian Wandell Thorball; Jacques Fellay; Jürg Böni; Sabine Yerly; Matthieu Perreau; Hans H Hirsch; Katharina Kusejko; Maria Christine Thurnheer; Manuel Battegay; Matthias Cavassini; Christian R Kahlert; Enos Bernasconi; Huldrych F Günthard; Roger D Kouyos Journal: Elife Date: 2021-06-01 Impact factor: 8.140